Literature DB >> 15531118

[Genetic polymorphism of cytomegalovirus strains responsible of congenital infections].

Olivier Picone1, Jean-Marc Costa, Yves Ville, Marie-Laure Chaix, Christine Rouzioux, Marianne Leruez-Ville.   

Abstract

OBJECTIVES: Congenital Cytomegalovirus (CMV) infection is the main cause of neurological handicap in young children. The objective for studying genetic polymorphism of strains responsible for congenital infection is to identify CMV strains or groups of strains which would be more frequent in this context and/or which would be responsible for more severe congenital infection.
METHODS: In this paper, we report and analyze the literature concerning the genetic polymorphism of CMV strains responsible of congenital infection, in the genes coding for the envelop protein B and the non structural UL144 protein and in the CMV short tandem repeats. RESULTS AND
CONCLUSION: All UL144 and gB genotypes can be vertically transmitted from mothers to fetuses, none of these studies has shown any link between the genotypes and the severity of congenital disease. Moreover, no link between short tandem repeats polymorphism and severity of congenital disease has been demonstrated. However, short tandem repeats analysis may be a powerful tool to study the epidemiology of CMV congenital infections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531118     DOI: 10.1016/j.patbio.2004.09.004

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  2 in total

1.  Quantitative and qualitative analysis of fetal temporal lobe T2 signal in cytomegalovirus infected fetuses and normal controls.

Authors:  Larisa Gorenstein; Eldad Katorza; Omer Bar-Yosef; Chen Hoffmann; Shai Shrot
Journal:  Quant Imaging Med Surg       Date:  2021-10

2.  The myeloid transcription factor GATA-2 regulates the viral UL144 gene during human cytomegalovirus latency in an isolate-specific manner.

Authors:  Emma Poole; Anett Walther; Kathy Raven; Christopher A Benedict; Gavin M Mason; John Sinclair
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.